Patents by Inventor Mark E. Furth
Mark E. Furth has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20170096641Abstract: Hepatic progenitors comprise two populations of human hepatic stem cells, primitive and proximal hepatic stem cells, and two populations of committed progenitors, one for biliary cells and one for hepatocytes. Human primitive hepatic stem cells are a very small fraction of the liver cell population and give rise to proximal hepatic stem cells constituting a much larger fraction of the liver. Human proximal hepatic stem cells give rise to biliary and hepatocyte committed progenitors. Primitive and proximal stem cells are the primary stem cells for the human liver. Human primitive hepatic stem cells may be isolated by immunoselection from human livers or culturing human liver cells under conditions which select for a human primitive hepatic stem cell. Proximal hepatic stem cells may be isolated by immunoselection, or by culturing human liver cells under conditions which include a developmental factor.Type: ApplicationFiled: October 12, 2016Publication date: April 6, 2017Applicants: Vesta Therapeutics Inc., University of North Carolina at Chapel HillInventors: Lola M. REID, Nicholas MOSS, Mark E. FURTH, John W. LUDLOW, Andrew T. BRUCE
-
Publication number: 20140302601Abstract: Hepatic progenitors comprise two populations of human hepatic stem cells, primitive and proximal hepatic stem cells, and two populations of committed progenitors, one for biliary cells and one for hepatocytes. Human primitive hepatic stem cells are a very small fraction of the liver cell population and give rise to proximal hepatic stem cells constituting a much larger fraction of the liver. Human proximal hepatic stem cells give rise to biliary and hepatocyte committed progenitors. Primitive and proximal stem cells are the primary stem cells for the human liver. Human primitive hepatic stem cells may be isolated by immunoselection from human livers or culturing human liver cells under conditions which select for a human primitive hepatic stem cell. Proximal hepatic stem cells may be isolated by immunoselection, or by culturing human liver cells under conditions which include a developmental factor.Type: ApplicationFiled: April 3, 2014Publication date: October 9, 2014Applicants: University of North Carolina at Chapel Hill, Vesta Therapeutics Inc.Inventors: Lola M. REID, Nicholas MOSS, Mark E. FURTH, John W. LUDLOW, Andrew T. BRUCE
-
Patent number: 8691523Abstract: Hepatic progenitors comprise two populations of human hepatic stem cells, primitive and proximal hepatic stem cells, and two populations of committed progenitors, one for biliary cells and one for hepatocytes. Human primitive hepatic stem cells are a very small fraction of the liver cell population and give rise to proximal hepatic stem cells constituting a much larger fraction of the liver. Human proximal hepatic stem cells give rise to biliary and hepatocyte committed progenitors. Primitive and proximal stem cells are the primary stem cells for the human liver. Human primitive hepatic stem cells may be isolated by immunoselection from human livers or culturing human liver cells under conditions which select for a human primitive hepatic stem cell. Proximal hepatic stem cells may be isolated by immunoselection, or by culturing human liver cells under conditions which include a developmental factor.Type: GrantFiled: December 12, 2006Date of Patent: April 8, 2014Assignees: Vesta Therapeautics, Inc., University of North Carolina at Chapel HillInventors: Lola M. Reid, Nicholas Moss, Mark E. Furth, John W. Ludlow, Andrew T. Bruce
-
Publication number: 20100112689Abstract: The present invention is directed toward a method for obtaining from whole liver or a resection thereof a population of cells comprising viable, functional liver cells enriched in hepatocytes and hepatocyte stem/progenitor cells, compositions thereof, and uses therefore. Compositions include a composition of liver cells enriched in hepatocytes and hepatocyte stem/progenitor cells and a pharmaceutical composition thereof. Uses include treatment of liver diseases, regeneration of liver, toxicity testing, and liver assist devices.Type: ApplicationFiled: May 13, 2009Publication date: May 6, 2010Inventors: John W. Ludlow, Mark E. Furth, Andrew T. Bruce, Lola M. Reid, Robert L. Susick, JR.
-
Publication number: 20040110289Abstract: The present invention is directed toward a method for obtaining from whole liver or a resection thereof a population of cells comprising viable, functional liver cells enriched in hepatocytes and hepatocyte stem/progenitor cells, compositions thereof, and uses therefore. Compositions include a composition of liver cells enriched in hepatocytes and hepatocyte stem/progenitor cells and a pharmaceutical composition thereof. Uses include treatment of liver diseases, regeneration of liver, toxicity testing, and liver assist devices.Type: ApplicationFiled: July 17, 2003Publication date: June 10, 2004Inventors: John W. Ludlow, Mark E. Furth, Andrew T. Bruce, Lola M. Reid, Robert L. Susick
-
Publication number: 20040018621Abstract: Hepatic progenitors comprise two populations of human hepatic stem cells, primitive and proximal hepatic stem cells, and two populations of committed progenitors, one for biliary cells and one for hepatocytes. Human primitive hepatic stem cells are a very small fraction of the liver cell population and give rise to proximal hepatic stem cells constituting a much larger fraction of the liver. Human proximal hepatic stem cells give rise to biliary and hepatocyte committed progenitors. Primitive and proximal stem cells are the primary stem cells for the human liver. Human primitive hepatic stem cells may be isolated by immunoselection from human livers or culturing human liver cells under conditions which select for a human primitive hepatic stem cell. Proximal hepatic stem cells may be isolated by immunoselection, or by culturing human liver cells under conditions which include a developmental factor.Type: ApplicationFiled: March 14, 2003Publication date: January 29, 2004Inventors: Lola Reid, Nick Moss, Mark E. Furth, John W. Ludlow, Andrew T. Bruce
-
Patent number: 6602687Abstract: The present invention relates to nucleic acid sequences encoding ciliary neurotrophic factor (CNTF) and to the proteins, peptides, and derivatives produced therefrom. In various embodiments of the invention, the nucleic acid sequences, proteins, and peptides of the invention may be used in the treatment of a variety of neurological diseases and disorders, including Alzheimer's disease. In a specific embodiment of the invention, CNTF may be used to support the growth of spinal cord neurons, thereby providing a method of treating spinal cord damage caused by trauma infarction, infection, nutritional deficiency or toxic agents. The present invention also relates to a novel method for producing substantilly pure CNTF. The invention also relates to pharmaceutical compositions comprising effective amounts of CNTF gene products which may be used in the diagnosis and treatment of a variety of neurologial diseases and disorders.Type: GrantFiled: May 8, 1992Date of Patent: August 5, 2003Assignee: Regeneron Pharmaceuticals, Inc.Inventors: Michael Sendtner, Kurt Stockli-Rippstein, Friedrich Lottspeich, Yoshihiro Arakawa, Patrick Desmond Carroll, Rudolf Georg Gotz, Georg W. Kreutzberg, Dan B. Lindholm, Piotr Masiakowski, Vivien Wong, Nancy Ip, Mark E. Furth, Nikos Panayotatos, Hans Thoenen
-
Patent number: 6316206Abstract: The present invention relates to the ciliary neurotrophic factor (CNTF) receptor, and provides for CNTF receptor nucleic acid and amino acid sequences. It also relates to (i) assay systems for detecting CNTF activity; (ii) experimental model systems for studying the physiologic role of CNTF; (ii) diagnostic techniques for identifying CNTF-related neurologic conditions; (iv) therapeutic techniques for the treatment of CNTF-related neurologic and muscular conditions, and (v) methods for identifying molecules homologous to CNTF and CNTFR.Type: GrantFiled: December 14, 1998Date of Patent: November 13, 2001Assignee: Regeneron Pharmaceuticals, Inc.Inventors: Samuel Davis, Stephen P. Squinto, Mark E. Furth, George D. Yancopoulos
-
Patent number: 5892003Abstract: The present invention relates to the ciliary neurotropic factor (CNTF) receptor, and provides for CNTF receptor antibodies. It also relates to diagnostic techniques for identifying CNTF-related neurologic conditions.Type: GrantFiled: January 11, 1996Date of Patent: April 6, 1999Assignee: Regeneron Pharmaceuticals, Inc.Inventors: Samuel Davis, Stephen P. Squinto, Mark E. Furth, George D. Yancopoulos
-
Patent number: 5849897Abstract: The present invention relates to the ciliary neurotrophic factor (CNTF) receptor, and provides for CNTF receptor nucleic acid and amino acid sequences. It also relates to (i) assay systems for detecting CNTF activity; (ii) experimental model systems for studying the physiologic role of CNTF; (ii) diagnostic techniques for identifying CNTF-related neurologic conditions; (iv) therapeutic techniques for the treatment of CNTF-related neurologic and muscular conditions, and (v) methods for identifying molecules homologous to CNTF and CNTFR.Type: GrantFiled: May 19, 1995Date of Patent: December 15, 1998Assignee: Regeneron Pharmaceuticals, Inc.Inventors: Samuel Davis, Stephen P. Squinto, Mark E. Furth, George D. Yancopoulos
-
Patent number: 5648334Abstract: The present invention relates to a method of treatment of a neuromuscular or muscle disorder resulting from the loss of axonal contact with the muscle comprising administering an effective amount of ciliary neurotrophic factor. The invention also relates to a method of treatment of a disorder of a type of tissue or cell resulting from the loss of axonal contact with the cell comprising administering an effective amount of ciliary neurotrophic factor in which the type of tissue or cell expresses a CNTF receptor protein.Type: GrantFiled: May 24, 1995Date of Patent: July 15, 1997Assignee: Regeneron Pharmaceuticals, Inc.Inventors: Samuel Davis, Stephen P. Squinto, Mark E. Furth, George D. Yancopoulos
-
Patent number: 5622862Abstract: The present invention provides for assay systems that may be used to detect and/or measure neurotrophin activity or to identify agents that exhibit neurotrophin-like activity, and for methods of using such assay systems. It is based, at least in part, on the discovery that the trkB protooncogene encodes a tyrosine kinase receptor that may serve as a functional binding protein for BDNF and NT-3. Such assay systems may be of particular value in identifying new neurotrophins or agents with neurotrophin-like activity. In various embodiments, the assay systems and methods of the invention may be used to detect and/or measure the binding of neurotrophin to trkB, either using direct binding studies or the detection of the secondary affects of trkB/neurotrophin binding. The present invention also has diagnostic and therapeutic utilities. In particular embodiments of the invention, methods of detecting aberrancies in trkB function or expression may be used in the diagnosis of neurological disorders.Type: GrantFiled: November 14, 1994Date of Patent: April 22, 1997Assignee: Regeneron Pharmaceuticals, Inc.Inventors: Stephen P. Squinto, David Glass, Thomas H. Aldrich, Peter DiStefano, Trevor Stitt, Mark E. Furth, George D. Yancopoulos
-
Patent number: 5512661Abstract: The present invention relates to chimeric neurotrophic factors which comprise at least a portion of a naturally occurring cellular factor and a portion of at least one other molecule such that the resulting chimeric molecule has neurotrophic activity. It is based, in part, on the discovery that chimeric molecules comprising portions of both NGF and BDNF are likely to possess neurotrotrophic activity, and in some cases exhibit a spectrum of activity larger than that of either parent molecule. It is further based on the discovery that chimeric molecules comprising neurotrophic factor sequences as well as additional peptide sequences may retain neurotrophic activity, and in some cases may exhibit a more potent activity than the parent factor. The chimeric neurotrophic factor molecules of the invention provide a number of advantages relative to naturally occurring neurotrophic factors.Type: GrantFiled: September 19, 1994Date of Patent: April 30, 1996Assignee: Regeneron Pharmaceuticals, Inc.Inventors: Eric M. Shooter, Ulrich Suter, Nancy P. Ip, Stephen P. Squinto, Mark E. Furth, Ronald M. Lindsay
-
Patent number: 5426177Abstract: The present invention relates to the ciliary neurotrophic factor (CNTF) receptor, and provides for CNTF receptor nucleic acid and amino acid sequences. It also relates to (i) assay systems for detecting CNTF activity; (ii) experimental model systems for studying the physiologic role of CNTF; (ii) diagnostic techniques for identifying CNTF-related neurologic conditions; (iv) therapeutic techniques for the treatment of CNTF-related neurologic and muscular conditions, and (v) methods for identifying molecules homologous to CNTF and CNTFR.Type: GrantFiled: March 28, 1991Date of Patent: June 20, 1995Assignee: Regeneron Pharmaceuticals, Inc.Inventors: Samuel Davis, Stephen P. Squinto, Mark E. Furth, George D. Yancopoulos
-
Patent number: 5169764Abstract: The present invention relates to chimeric neurotrophic factors which comprise at least a portion of a naturally occurring cellular factor and a portion of at least one other molecule such that the resulting chimeric molecule has neurotrophic activity. It is based, in part, on the discovery that chimeric molecules comprising portions of both NGF and BDNF are likely to possess neurotrotrophic activity, and in some cases exhibit a spectrum of activity larger than that of either parent molecule. It is further based on the discovery that chimeric molecules comprising neurotrophic factor sequences as well as additional peptide sequences may retain neurotrophic activity, and in some cases may exhibit a more potent activity than the parent factor. The chimeric neurotrophic factor molecules of the invention provide a number of advantages relative to naturally occurring neurotrophic factors.Type: GrantFiled: August 8, 1990Date of Patent: December 8, 1992Assignee: Regeneron Pharmaceuticals, Inc.Inventors: Eric M. Shooter, Ulrich Suter, Nancy Ip, Stephen P. Squinto, Mark E. Furth, Ronald M. Lindsay, George D. Yancopoulos